Skip to main content
Top
Published in: Strahlentherapie und Onkologie 9/2012

01-09-2012 | Original article

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission

Results of a multivariate analysis

Authors: C. Matuschek, PD Dr. E. Bölke, S.L. Roth, K. Orth, I. Lang, H. Bojar, J.W. Janni, W. Audretsch, C. Nestle-Kraemling, G. Lammering, V. Speer, S. Gripp, P.A. Gerber, B.A. Buhren, R. Sauer, M. Peiper, M. Schauer, M. Dommach, K. Struse-Soll, W. Budach

Published in: Strahlentherapie und Onkologie | Issue 9/2012

Login to get access

Abstract

Background

An earlier published series of neoadjuvant radiochemotherapy (NRT-CHX) in locally advanced noninflammatory breast cancer (LABC) has now been updated with a follow-up of more than 15 years. Long-term outcome data and predictive factors for pathologic complete response (pCR) were analyzed.

Patients and methods

During 1991–1998, 315 LABC patients (cT1-cT4/cN0-N1) were treated with NRT-CHX. Preoperative radiotherapy (RT) consisted of external beam radiation therapy (EBRT) of 50 Gy (5 × 2 Gy/week) to the breast and the supra-/infraclavicular lymph nodes combined with an electron boost in 214 cases afterwards or—in case of breast conservation—a 10-Gy interstitial boost with 192Ir afterloading before EBRT. Chemotherapy was administered prior to RT in 192 patients, and concomitantly in 113; 10 patients received no chemotherapy. The update of all follow-up ended in November 2011. Age, tumor grade, nodal status, hormone receptor status, simultaneous vs. sequential CHX, and the time interval between end of RT and surgery were examined in multivariate terms with pCR and overall survival as end point.

Results

The total pCR rate after neoadjuvant RT-CHX reached 29.2%, with LABC breast conservation becoming possible in 50.8% of cases. In initially node-positive cases (cN+), a complete nodal response (pN0) after NRT-CHX was observed in 56% (89/159). The multivariate analysis revealed that a longer time interval to surgery increased the probability for a pCR (HR 1.17 [95% CI 1.05–1.31], p < 0.01). However, in large tumors (T3–T4) a significantly reduced pCR rate (HR 0.89 [95% CI 0.80–0.99], p = 0.03) was obtained. Importantly, pCR was the strongest prognostic factor for long-term survival (HR 0.28 [95% CI 0.19–0.56], p < 0.001).

Conclusion

pCR identifies patients with a significantly better prognosis for long-term survival. However, a long time interval to surgery (> 2 months) increases the probability of pCR after NRT-CHX.
Literature
1.
go back to reference Roth SL, Audretsch W, Bojar H et al (2010) Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol 186:299–306PubMedCrossRef Roth SL, Audretsch W, Bojar H et al (2010) Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol 186:299–306PubMedCrossRef
2.
go back to reference Hung WK, Lau Y, Chan CM, Yip AW (2000) Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study. Hong Kong Med J 6:265–268PubMed Hung WK, Lau Y, Chan CM, Yip AW (2000) Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study. Hong Kong Med J 6:265–268PubMed
3.
go back to reference Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302PubMedCrossRef Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302PubMedCrossRef
4.
go back to reference Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199PubMedCrossRef Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199PubMedCrossRef
5.
go back to reference Wildiers H, Neven P, Christiaens MR et al (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22:588–594PubMedCrossRef Wildiers H, Neven P, Christiaens MR et al (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22:588–594PubMedCrossRef
6.
go back to reference Audretsch W, Andree C (2012) Advancements in oncoplastic surgery of the breast. In: Babiera GV et al (eds) Advanced Therapy of Breast Disease, 3rd edn. PMPH, pp 613–642 Audretsch W, Andree C (2012) Advancements in oncoplastic surgery of the breast. In: Babiera GV et al (eds) Advanced Therapy of Breast Disease, 3rd edn. PMPH, pp 613–642
7.
go back to reference Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed
8.
9.
go back to reference Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef
10.
go back to reference Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347–354PubMed Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347–354PubMed
11.
go back to reference Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed
12.
go back to reference Scholl SM, Pierga JY, Asselain B et al (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969–1975PubMedCrossRef Scholl SM, Pierga JY, Asselain B et al (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969–1975PubMedCrossRef
13.
go back to reference Shanta V, Swaminathan R, Rama R, Radhika R (2008) Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys 70:51–58PubMedCrossRef Shanta V, Swaminathan R, Rama R, Radhika R (2008) Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys 70:51–58PubMedCrossRef
14.
go back to reference Lerouge D, Touboul E, Lefranc JP et al (2004) Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 59:1062–1073PubMedCrossRef Lerouge D, Touboul E, Lefranc JP et al (2004) Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 59:1062–1073PubMedCrossRef
15.
go back to reference Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef
16.
go back to reference Koscielny S, Tubiana M, Le MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715PubMedCrossRef Koscielny S, Tubiana M, Le MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715PubMedCrossRef
17.
go back to reference Withers HR, Thames HD (1988) Dose fractionation and volume effects in normal tissues and tumors. Am J Clin Oncol 11:313–329PubMedCrossRef Withers HR, Thames HD (1988) Dose fractionation and volume effects in normal tissues and tumors. Am J Clin Oncol 11:313–329PubMedCrossRef
18.
go back to reference Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef
19.
go back to reference Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef
20.
go back to reference Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed
21.
go back to reference Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207–213PubMedCrossRef Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207–213PubMedCrossRef
22.
go back to reference Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516PubMedCrossRef Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516PubMedCrossRef
23.
go back to reference Audretsch W, Rezai M, Kolotas C et al (1994) Oncoplastic surgery: “Target” volume reduction, lumpectomy reconstruction and flap-supported operability in breast cancer. Proceedings 2nd European Congress on Senology, Vienna, Austria, October 2–6. Mendoza Bologna, Italy, pp 139–157 Audretsch W, Rezai M, Kolotas C et al (1994) Oncoplastic surgery: “Target” volume reduction, lumpectomy reconstruction and flap-supported operability in breast cancer. Proceedings 2nd European Congress on Senology, Vienna, Austria, October 2–6. Mendoza Bologna, Italy, pp 139–157
24.
go back to reference Audretsch W, Rezai M, Kolotas C et al (1989) Tumor-specific immediate reconstruction (TSIR) in breast cancer patients. Perspect Plast Surg 11:71–106 Audretsch W, Rezai M, Kolotas C et al (1989) Tumor-specific immediate reconstruction (TSIR) in breast cancer patients. Perspect Plast Surg 11:71–106
Metadata
Title
Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission
Results of a multivariate analysis
Authors
C. Matuschek
PD Dr. E. Bölke
S.L. Roth
K. Orth
I. Lang
H. Bojar
J.W. Janni
W. Audretsch
C. Nestle-Kraemling
G. Lammering
V. Speer
S. Gripp
P.A. Gerber
B.A. Buhren
R. Sauer
M. Peiper
M. Schauer
M. Dommach
K. Struse-Soll
W. Budach
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 9/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0162-8

Other articles of this Issue 9/2012

Strahlentherapie und Onkologie 9/2012 Go to the issue

Mitteilungen der Fachgesellschaften

Mitteilungen